-+ 0.00%
-+ 0.00%
-+ 0.00%

Medicus Pharma Q1 FY26 net loss widens 77.22% to $9.04 million

PUBT·05/14/2026 20:12:36
Listen to the news
Medicus Pharma Q1 FY26 net loss widens 77.22% to $9.04 million
  • Medicus Pharma posted a net loss of USD 9.04 million for the quarter ended March 31, 2026, widening from the prior-year period; loss per share narrowed to USD 0.31.
  • Operating loss widened to USD 8.6 million as total operating expenses climbed 67.7% to USD 8.6 million.
  • General and administrative expense rose 88.9% to USD 5.89 million, while R&D increased 34.8% to USD 2.7 million.
  • Cash and cash equivalents totaled USD 6.37 million at quarter-end; cash used in operating activities deepened to USD 8.97 million.
  • Phase 2 SKNJCT-003 SkinJect dataset showed 73% clinical clearance in the 200-µg cohort at Day 57, with FDA “study may proceed” clearance received to start a Phase 2b dose-optimization study of Teverelix in advanced prostate cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062993-26-002629), on May 14, 2026, and is solely responsible for the information contained therein.